BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 16735696)

  • 1. Dynamics of CD81 expression on lymphocyte subsets during interferon-alpha-based antiviral treatment of patients with chronic hepatitis C.
    Kronenberger B; Herrmann E; Hofmann WP; Wedemeyer H; Sester M; Mihm U; Ghaliai T; Zeuzem S; Sarrazin C
    J Leukoc Biol; 2006 Aug; 80(2):298-308. PubMed ID: 16735696
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD81 expression in peripheral blood lymphocytes before and after treatment with interferon and ribavirin in HIV/HCV coinfected patients.
    Micheloud D; González-Nicolás J; Berenguer J; Lorente R; Miralles P; López JC; Cosín J; Catalán P; Muñoz-Fernández M; Resino S
    HIV Med; 2010 Mar; 11(3):161-9. PubMed ID: 19780859
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD81 down-regulation on B cells is associated with the response to interferon-alpha-based treatment for chronic hepatitis C virus infection.
    Chang LL; Cheng PN; Chen JS; Young KC
    Antiviral Res; 2007 Jul; 75(1):43-51. PubMed ID: 17194487
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interferon alfa down-regulates CD81 in patients with chronic hepatitis C.
    Kronenberger B; Rüster B; Elez R; Weber S; Piiper A; Lee JH; Roth WK; Zeuzem S
    Hepatology; 2001 Jun; 33(6):1518-26. PubMed ID: 11391542
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expansion of functionally skewed CD56-negative NK cells in chronic hepatitis C virus infection: correlation with outcome of pegylated IFN-alpha and ribavirin treatment.
    Gonzalez VD; Falconer K; Björkström NK; Blom KG; Weiland O; Ljunggren HG; Alaeus A; Sandberg JK
    J Immunol; 2009 Nov; 183(10):6612-8. PubMed ID: 19846870
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD81 expression on CD19+ peripheral blood lymphocytes is associated with chronic HCV disease and increased risk for HCV infection: a putative role for inflammatory cytokines.
    D'Agosto G; Trento E; Nosotti L; Bordignon V; Battista M; Prignano G; Pimpinelli F; Biolcati G; Macrì A; Palamara G; Miglioresi L; Morrone A; Di Carlo A; Cordiali-Fei P; Ensoli F
    J Biol Regul Homeost Agents; 2009; 23(3):155-64. PubMed ID: 19828092
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD81 expression for discrimination between sustained virologic response and relapse in patients with chronic hepatitis C.
    Welker MW; Hofmann WP; Lange CM; Herrmann E; Sarrazin C; Zeuzem S; Kronenberger B
    Scand J Gastroenterol; 2011 Jul; 46(7-8):973-80. PubMed ID: 21615225
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A prospective study of T- and B-lymphocyte subpopulations, CD81 expression levels on B cells and regulatory CD4(+) CD25(+) CD127(low/-) FoxP3(+) T cells in patients with chronic HCV infection during pegylated interferon-alpha2a plus ribavirin treatment.
    Soldevila B; Alonso N; Martínez-Arconada MJ; Morillas RM; Planas R; Sanmartí AM; Martínez-Cáceres EM
    J Viral Hepat; 2011 Jun; 18(6):384-92. PubMed ID: 20487258
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term follow-up after successful interferon therapy of acute hepatitis C.
    Wiegand J; Jäckel E; Cornberg M; Hinrichsen H; Dietrich M; Kroeger J; Fritsch WP; Kubitschke A; Aslan N; Tillmann HL; Manns MP; Wedemeyer H
    Hepatology; 2004 Jul; 40(1):98-107. PubMed ID: 15239091
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased proportion of the CD56(bright) NK cell subset in patients chronically infected with hepatitis C virus (HCV) receiving interferon-alpha and ribavirin therapy.
    Lee S; Watson MW; Flexman JP; Cheng W; Hammond T; Price P
    J Med Virol; 2010 Apr; 82(4):568-74. PubMed ID: 20166183
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutations within the CD81-binding sites and hypervariable region 2 of the envelope 2 protein: correlation with treatment response in hepatitis C virus-infected patients.
    Hofmann WP; Sarrazin C; Kronenberger B; Schönberger B; Bruch K; Zeuzem S
    J Infect Dis; 2003 Mar; 187(6):982-7. PubMed ID: 12660945
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The dynamics of T-lymphocyte responses during combination therapy for chronic hepatitis C virus infection.
    Barnes E; Harcourt G; Brown D; Lucas M; Phillips R; Dusheiko G; Klenerman P
    Hepatology; 2002 Sep; 36(3):743-54. PubMed ID: 12198669
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impaired ability of interferon-alpha-primed dendritic cells to stimulate Th1-type CD4 T-cell response in chronic hepatitis C virus infection.
    Miyatake H; Kanto T; Inoue M; Sakakibara M; Kaimori A; Yakushijin T; Itose I; Miyazaki M; Kuzushita N; Hiramatsu N; Takehara T; Kasahara A; Hayashi N
    J Viral Hepat; 2007 Jun; 14(6):404-12. PubMed ID: 17501761
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Influence of interferon-alpha therapy on the count and function of T lymphocytes in children with chronic hepatitis C].
    Woźniakowska-Gesicka T; Wiśniewska-Ligier M; Kupś J; Borowska-Rybus B; Sułat-Syncerek D; Grzegorczyk W
    Pol Merkur Lekarski; 2001 Oct; 11(64):344-7. PubMed ID: 11770316
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Binding of HCV E2 to CD81 induces RANTES secretion and internalization of CC chemokine receptor 5.
    Nattermann J; Nischalke HD; Feldmann G; Ahlenstiel G; Sauerbruch T; Spengler U
    J Viral Hepat; 2004 Nov; 11(6):519-26. PubMed ID: 15500552
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Different viral kinetics between hepatitis C virus genotype 1 and 2 as on-treatment predictors of response to a 24-week course of high-dose interferon-alpha plus ribavirin combination therapy.
    Yu ML; Chuang WL; Dai CY; Lee LP; Hsieh MY; Lin ZY; Chen SC; Hsieh MY; Wang LY; Chang WY; Tsai SL; Kuo HT
    Transl Res; 2006 Sep; 148(3):120-7. PubMed ID: 16938649
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HCV kinetics, quasispecies, and clearance in treated HCV-infected and HCV/HIV-1-coinfected patients with hemophilia.
    Shire NJ; Horn PS; Rouster SD; Stanford S; Eyster ME; Sherman KE;
    Hepatology; 2006 Nov; 44(5):1146-57. PubMed ID: 17058240
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutations in the putative HCV-E2 CD81 binding regions and correlation with cell surface CD81 expression.
    Kronenberger B; Sarrazin C; Hofmann WP; von Wagner M; Herrmann E; Welsch C; Elez R; Rüster B; Piiper A; Zeuzem S
    J Viral Hepat; 2004 Jul; 11(4):310-8. PubMed ID: 15230853
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunological predictors of different responses to combination therapy with interferon alpha and ribavirin in patients with chronic hepatitis C.
    Amaraa R; Mareckova H; Urbanek P; Fucikova T
    J Gastroenterol; 2003; 38(3):254-9. PubMed ID: 12673448
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Virus-specific T-cell responses associated with hepatitis C virus (HCV) persistence in the liver after apparent recovery from HCV infection.
    Quiroga JA; Llorente S; Castillo I; Rodríguez-Iñigo E; López-Alcorocho JM; Pardo M; Carreño V
    J Med Virol; 2006 Sep; 78(9):1190-7. PubMed ID: 16847959
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.